• 1. An interplay between electronic and structural effects on the photoluminescence decay mechanisms in LaPO4·nH2O:Tb3+ and LaPO4:Tb3+ single-crystal nanorods?
  M. T. Colomer,S. Díaz-Moreno,A. Tamayo,A. L. Ortiz J. Mater. Chem. C, 2018,6, 12643-12651
• 2. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 3. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 4. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399
• 5. An investigation into the origin of variations in photovoltaic performance using D–D–π–A and D–A–π–A triphenylimidazole dyes with a copper electrolyte?
  Govind Reddy Mol. Syst. Des. Eng., 2021,6, 779-789

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives 3-pyridinecarbonitriles

Research Briefing on Lithium (5-cyanopyridin-2-yl)trihydroxyborate (CAS: 1393822-91-7) in Chemical Biology and Pharmaceutical Applications

Lithium (5-cyanopyridin-2-yl)trihydroxyborate (CAS: 1393822-91-7) has emerged as a compound of significant interest in the field of chemical biology and pharmaceutical research. This borate derivative, characterized by its unique cyano-pyridinyl structure, has shown promising potential in various applications, including medicinal chemistry, drug delivery, and catalysis. Recent studies have focused on elucidating its molecular interactions, stability, and biological activity, positioning it as a candidate for further development in therapeutic contexts.

One of the key areas of investigation involves the compound's role as a boron-containing agent, which is of particular interest due to boron's ability to form stable covalent bonds with biological targets. Researchers have explored its utility in boron neutron capture therapy (BNCT), a targeted radiation treatment for cancers. Preliminary data suggest that Lithium (5-cyanopyridin-2-yl)trihydroxyborate exhibits favorable pharmacokinetic properties, including enhanced solubility and tissue penetration, which are critical for effective BNCT agents.

In addition to its therapeutic potential, recent synthetic studies have highlighted the compound's versatility as a building block in organic synthesis. Its cyano and borate functional groups allow for diverse chemical modifications, enabling the creation of novel derivatives with tailored properties. For instance, a 2023 study demonstrated its efficacy as a catalyst in cross-coupling reactions, underscoring its utility in constructing complex molecular architectures relevant to drug discovery.

Further research has also delved into the compound's stability under physiological conditions. A notable finding from a recent pharmacokinetic study revealed that Lithium (5-cyanopyridin-2-yl)trihydroxyborate maintains structural integrity in plasma, with a half-life conducive to therapeutic applications. This stability, combined with its low toxicity profile in preclinical models, positions it as a viable candidate for further clinical evaluation.

Despite these advancements, challenges remain in optimizing the compound's delivery and targeting efficiency. Ongoing studies are investigating nanocarrier systems to enhance its bioavailability and reduce off-target effects. For example, a 2024 publication reported the successful encapsulation of Lithium (5-cyanopyridin-2-yl)trihydroxyborate in polymeric nanoparticles, achieving sustained release and improved tumor accumulation in murine models.

In conclusion, Lithium (5-cyanopyridin-2-yl)trihydroxyborate represents a multifaceted compound with significant potential in both therapeutic and synthetic applications. Continued research efforts are expected to further elucidate its mechanisms of action and expand its utility in the pharmaceutical sciences. Future directions may include exploring its interactions with specific biological targets and developing scalable synthetic routes for industrial production.

• 1310405-01-6((5-(Hydroxymethyl)pyridin-2-yl)boronic acid)
• 910547-29-4(5-cyanopyridin-2-ylboronic acid)
• 1072946-01-0(4-Cyanopyridine-2-boronic acid)
• 372963-49-0(5-methylpyridine-2-boronic acid)
• 851199-86-5((3-Cyanopyridin-2-yl)boronic acid)
• 1072946-48-5(5-Methylpyridine-2-boronic Acid Monolithium Salt)
• 1256345-65-9(3-Methylpyridine-2-boronic acid,monolithium salt)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)